Vaxcyte IncNASDAQ:PCVX
- LAST PRICE73.4500
- TODAY'S CHANGE (%)-0.5600 (-0.7567%)
- Bid / Lots73.0500/ 4
- Ask / Lots73.7500/ 3
- Open / Previous Close73.0600 / 74.0100
- Day Range
- 52 Week Range
- Volume5,442
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PCVX |
|---|---|---|
| 09:32 ET | 4030 | 72.89 |
| 09:36 ET | 393 | 73.45 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vaxcyte Inc | 8.0B | -17.4x | --- |
Cerevel Therapeutics Holdings Inc | 7.5B | -15.3x | --- |
Revolution Medicines Inc | 6.6B | -10.4x | --- |
Cytokinetics Inc | 6.3B | -9.7x | --- |
Madrigal Pharmaceuticals Inc | 6.1B | -11.9x | --- |
Legend Biotech Corp | 8.3B | -16.5x | --- |
Company Information
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
Contact Information
- Headquarters
- 825 INDUSTRIAL ROAD, STE. 300SAN CARLOS, CA, United States 94070
- Phone
- 650-837-0111
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Carlos Paya
- President, Chief Financial Officer
- Andrew Guggenhime
- Chief Executive Officer, Co-Founder, Director
- Grant Pickering
- Executive Vice President, Chief Operating Officer
- James Wassil
- Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
- Mikhail Eydelman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.0B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 108.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.97 |
EPS | $-4.22 |
Book Value | $13.01 |
P/E Ratio | -17.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
